Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | HPGD | P15428 | 9/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358889 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDHSD17B10STS | |
| SCHEMBL15842713 | 0.81 | PGR (0.46) | ALDH1A1KDM4ECA12CA9PGR | |
| SCHEMBL30636721 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL67818 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL11340455 | 0.77 | MAPT (0.52) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL548410 | 0.76 | CYP2A6 (0.50) | ALDH1A1KDM4EHPGDCA12CA9 | |
| SCHEMBL27523022 | 0.75 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL718720 | 0.74 | NOS3 (0.40) | ALDH1A1KDM4EHPGDCYP3A4CYP1A2 | |
| SCHEMBL17861315 | 0.74 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10MAOA | |
| SCHEMBL10163685 | 0.74 | CDK9 (0.46) | ALDH1A1ALDH2SMN1; SMN2MAOBHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| CN-101142203-A | Novel coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1846386-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006078833-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | ALDH1A1 1678/4885KDM4E 3289/4885HPGD 2449/4885 |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | KCNN2, KCNH3, KCNN1 | ALDH1A1 1703/4885KDM4E 756/4885HPGD 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.